FX.co ★ MetaVia Announces Positive Phase 2a Clinical Data For DA-1241 In Patients With Presumed MASH

MetaVia Inc. (MTVA) reported positive outcomes from its dual-phase Phase 2a clinical trial of DA-1241 for patients suspected of having metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease. Over the 16-week trial period, the drug DA-1241, when combined with Sitagliptin, showed a statistically significant decrease in alanine transaminase levels. Additionally, the treatment met several secondary goals, such as reducing controlled attenuation parameters and hemoglobin A1C levels. MetaVia anticipates holding an end-of-Phase-2 meeting with the U.S. Food and Drug Administration (FDA) in the first half of 2025. As of now, MetaVia’s shares are trading at $1.84, reflecting a decrease of 17.71% on the Nasdaq.